

Special Issue

Synthetic DNA Vaccine

Message from the Guest Editors

Live attenuated and inactivated pathogens are used as conventional vaccines have the poor assurance of safety as they may return to pathogenic form. On the other hand, subunit DNA vaccines avoid the risk of reversion. Analysis of DNA vaccines show the minimal level of side effects, not integrating into the host chromosome, and does not have anti-vehicle autoimmunity after vaccination. Thus, making it possible to administer multiple doses. The main advantage of DNA vaccines is their ability to stimulate both the humoral and cellular arms of the adaptive immune system. The aim of this Special Issue is to collate original research that seeks to show the efficacy of DNA vaccines against pathogenic bacteria/virus/and parasitic infection.

Guest Editors

Dr. Imran Hussain Chowdhury

Department of Microbiology and Immunology, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA

Dr. Subhadip Choudhuri

Department of Microbiology & Immunology; University of Texas Medical Branch, Galveston, TX, USA

Deadline for manuscript submissions

closed (25 April 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/57758

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).